New drug ABBV-313 takes first step in human safety trial
NCT ID NCT07673120
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug called ABBV-313 in healthy adult volunteers. The main goal is to check if the drug is safe and how the body handles it, including how it is absorbed and broken down. Participants receive either the drug or a placebo as an injection or infusion. This study does not aim to treat any disease but is a necessary first step before testing ABBV-313 in people with a specific condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABBV-313
What this could lead to
If successful, this study could provide the safety data needed to move ABBV-313 into future trials for specific diseases.
What could go wrong
This is a very early phase 1 study in healthy volunteers, so it cannot show whether the drug works for any disease. Side effects are possible and will be closely monitored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Acpru /Id# 283495
RECRUITINGGrayslake, Illinois, 60030, United States